Clinical trial NCT01917669: A Pilot Feasibility Study of Fibroblast Calcium and Glucoregulation in Health and Disease
Official title: A Pilot Feasibility Study of Fibroblast Calcium and Glucoregulation in Health
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Type 2 Diabetes
Lead sponsor: University of Kentucky
Sponsor class: OTHER
Collaborators: name: American Diabetes Association
First posted: 2013-08-07
Enrollment: 0
Sex: ALL
Minimum age (years): 40
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: We will recruit both male and female participants. The age range for this study is 40-55 years old

Brief summary: The purpose of this research is to better understand how calcium and glucose may play a role in people developing diabetes. By doing this study, the investigator hopes to learn whether abnormal calcium and glucose responses in skin biopsies from healthy patients and patients with Type 2 diabetes can identify and predict patients at greatest risk for later complications.

Detailed description: The overall goal of this proposal is to establish a pathophysiological index of a patient's status through imaging of calcium and glucose in skin fibroblasts. The investigator will obtain skin samples from patients in the Barnstable Brown Obesity and Diabetes Center at the University of Kentucky to test the hypothesis that calcium and glucose dysregulation are present in fibroblasts from patients with Type 2 diabetes, and are exaggerated in more difficult-to-treat patients or those with poor glucose control. The innovation of the project focuses on results that can potentially lead to earlier treatment for patients with diabetes and thereby reduce the risk for long-term complications.

Three levels of analyses will be conducted to assess the relationship between Ca2+ and glucose homeostasis in four patient groups (lean non-diabetics, obese non-diabetics, Type 2 Diabetics with good glucose control, and Type 2 Diabetics with poor control.

Participants will be required to attend only one study visit that will last approximately 2-3 hours. During the study subject will undergo the following: 1. Collection of two 4 ml tubes of blood for adiponectin analysis, 2. A skin biopsy, 3. Collection and review of medical history and current/past medication use 4. Collection of demographic information, 5. Height and weight measurement 6. Body mass index evaluation, 7. Vital signs assessment (blood pressure, pulse).

Follow-up for all enrolled patients will occur on a yearly basis through a phone interview.

The punch biopsy will be performed under local anesthesia.

Eligibility criteria: Inclusion Criteria:

* Healthy
* Type 2 Diabetes

Exclusion Criteria:

* Under 40 years of age
* Over 55 years of age
* Pregnant or breastfeedig
* Will not agree to a skin biopsy
* Talking calcium channel blockers

Primary outcomes:
measure: Are peak (nM) calcium responses to bradykinin enhanced along the continuum of disease in skin fibroblasts from the 4 patient groups?
timeFrame: Three years
Secondary outcomes:
measure: Are glucose utilization rates (a.u./min) measured in skin fibroblasts from the 4 patient groups different with disease progression?
timeFrame: Three years
Other outcomes:
measure: What component of peripheral metabolic dysregulation (HbA1c (%), adiponectin (ug/mL), cholesterol (mg/dL)) is associated with changes in calcium responses (nM) in skin fibroblasts?
timeFrame: Three years
Locations:
city: Lexington
country: United States
facility: University of Kentucky Center for Clinical and Translational Science
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: Olivier Thibault, PhD
role: STUDY_DIRECTOR
References: